Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I trial of donor liver-derived activated NK cell immunotherapy after living-donor liver transplantation for hepatocellular carcinoma
jRCT2063260046Phase 1Recruiting
- Start
- Sep 2026
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of donor liver-derived activated natural killer cells in hepatocellular carcinoma (HCC) and Cirrhosis (2 cohorts), sponsored by none. Primary endpoint: Safety at 3 months after liver transplantation. Started Sep 2026; status: recruiting.
02
Drugs
donor liver-derived activated natural killer cells
03
Conditions
hepatocellular carcinoma (HCC)Cirrhosis
Beyond the preview
Go deeper on jRCT2063260046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2063260046.